IP Library Granted Patent US 8,221,981
Granted Patent B2
US 8,221,981 · App. 12/452,580 · Granted Jul 17, 2012

Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides

Assignee: Argos Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,981
App. No.
12/452,580
Granted
Jul 17, 2012
Kind
B2
Abstract

The invention relates to improved methods and compositions for the nucleic acid amplification of one or multiple variants (strains) of Human Immunodeficiency Virus (HIV) present in a sample, and preferably in a sample from a pathogen infected individual. In particular, novel primers, methods and kits for the amplification of one or more species of HIV Rev, Gag and Nef nucleic acids are provided. The amplified HIV nucleic acid can be used to identify and/or quantitate HIV variants present in a sample. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can also be used directly as vaccines or to transfect/load antigen presenting cells. The loaded antigen presenting cells can be used as a vaccine for the treatment or prevention of HIV infection.

Claims (53)

1. A composition comprising at least one or a combination of Rev T7 promoter primers selected from the group consisting of:

(SEQ ID NO: 24)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCACC

TCCCAACC,

(SEQ ID NO: 25)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCACC

TCCCAGCC,

(SEQ ID NO: 26)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCACC

TCCCAGTT,

(SEQ ID NO: 27)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCTTA

CCCCAACC,

(SEQ ID NO: 28)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCTTA

CCCCAAAC,

(SEQ ID NO: 29)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGGACCCTTA

CCCCAAGC,

(SEQ ID NO: 17)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

ACCT,

(SEQ ID NO: 18)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

GCCT,

(SEQ ID NO: 19)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

TCCT,

(SEQ ID NO: 20)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

ATAC,

(SEQ ID NO: 21)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGATCC

ATAC,

(SEQ ID NO: 22)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

TTAC,

and

(SEQ ID NO: 23)

N 1 N 2 N 3 N 4 N 5 TAATACGACTCACTATAGGN 6 AGACCACCATGTCAGACCC

CTAC;

wherein N 6 is G, A, C or T; and either N 1 is G, N 2 is A, N 3 is A and N 4 and N 5 are T or each of N 1 through N 5 are absent.

2. The composition of claim 1 , wherein N 1 is G, N 2 is A, N 3 is A and N 4 and N 5 are T.

3. The composition of claim 1 , wherein each of N 1 through N 5 are absent.

4. The composition of claim 1 , wherein N 6 is A, C or T.

5. The composition of claim 1 , wherein N 6 is G.

6. The composition of claim 1 , which comprises at least two primers selected from the group consisting of SEQ ID NO:24; SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29.

7. The composition of claim 6 , which comprises SEQ ID NO:24; SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29.

8. The composition of claim 6 , further comprising a Rev 64T reverse primer selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16, or any combination thereof.

9. The composition of claim 1 , which comprises at least two primers selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

10. The composition of claim 9 , which comprises SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

11. The composition of claim 9 , further comprising a Rev 64T reverse primer selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16, or any combination thereof.

12. A method for amplifying an HIV Rev nucleic acid, comprising carrying out a polymerase chain reaction using at least one or a combination of Rev T7 7912 forward primers selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ CD NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29; and at least one or a combination of Rev R8300 64T reverse primers selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO: 16.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2015
From: KIRIN HOLDINGS KABUSHIKI KAISHA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 036239/0051 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2012
From: TCHEREPANOVA, IRINA; STARR, AIJING; LACKFORD, BRAD
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 028025/0640 →
CHANGE OF NAME Recorded Jul 28, 2011
From: KIRIN BEER KABUSHIKI KAISHA
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 026667/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2011
From: TCHEREPANOVA, IRINA; STARR, AIJING; LACKFORD, BRAD
To: ARGOS THERAPEUTICS, INC.; KIRIN BEER KABUSHIKI KAISHA
Reel/Frame 026666/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2011
From: TCHEREPANOVA, IRINA; STARR, AIJING; LACKFORD, BRAD
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 026659/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2010
From: KYOWA HAKKO KIRIN CO., LTD.
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 024753/0219 →
Continuity (2)
Provisional Application 60962510 · Jul 30, 2007
Related Publication 20100136631A1 · Jun 3, 2010